Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shingo Toyoda

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Scientific Reports|July 27, 2025
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
International Journal of Clinical Oncology|September 2, 2024
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in JapanAkihiro Yoshimura, Taigo Kato, Yasutomo Nakai, et al.
Scientific Reports|December 12, 2025
Real-world efficacy and safety of pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma: a multi-institutional retrospective studyTaigo Kato, Yasutomo Nakai, Mototaka Sato, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Scientific Reports|July 27, 2025
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapyTatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, et al.
Pageof 4